Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology names Aziz Sawaf CFO, effective October 5, 2026

Neutral Impact 4 of 5 leadership Written later

Vir Biotechnology appointed Aziz Sawaf, formerly CFO of Theravance Biopharma, as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Brent Sabatini, who has been interim principal financial officer, will stop serving in that role and remain Senior Vice President and Chief Accounting Officer.

Key points

  • Sawaf's annualized base salary is $520,000, with a target bonus of 45% of base salary and a one-time cash sign-on bonus of $150,000.
  • Sawaf's offer includes an option to buy 150,000 shares and 75,000 restricted stock units, granted on or around November 15, 2026.
  • Under the Severance Plan, a covered termination after a change in control yields a lump sum of 12 months' base salary plus target bonus, while one outside that period yields nine months' base salary plus a pro-rated bonus.

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECOct 1, 2026, 8:34 AM ET
Accession number0001628280-26-064117

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.